Page last updated: 2024-08-23

lonidamine and Cancer of Ovary

lonidamine has been researched along with Cancer of Ovary in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's5 (50.00)18.2507
2000's2 (20.00)29.6817
2010's3 (30.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jin, X; Lv, H; Zhang, Z; Zhou, J1
Glickson, JD; Heitjan, DF; Leeper, DB; Nath, K; Nelson, DS; Zhou, R1
Amiji, M; Duan, Z; Milane, L1
Carlini, P; Cognetti, F; Di Cosimo, S; Fabi, A; Ferretti, G; Papaldo, P1
Brunetti, I; Conte, PF; Dargenio, F; Fanucchi, A; Gadducci, A; Giannessi, PG; Muttini, MP1
Bottalico, C; de Lena, M; Guerrieri, A; Lorusso, V; Micelli, G; Palmisano, F1
Bottalico, C; Brandi, M; Catino, A; De Lena, M; De Mitrio, A; Gargano, G; Guida, M; Latorre, A; Leone, B; Lorusso, V; Vallejo, C1
Bearzatto, A; De Marco, C; Orlandi, L; Silvestrini, R; Villa, R; Zaffaroni, N1
Caporusso, L; Catino, A; Crucitta, E; De Lena, M; Fanizza, G; Gargano, G; Guida, M; Latorre, A; Lorusso, V; Mazzei, A; Sambiasi, D1
Costa, A; Orlandi, L; Silvestrini, R; Villa, R; Zaffaroni, N1

Reviews

1 review(s) available for lonidamine and Cancer of Ovary

ArticleYear
Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors.
    Drugs of today (Barcelona, Spain : 1998), 2003, Volume: 39, Issue:3

    Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Female; Humans; Indazoles; Lung Neoplasms; Male; Ovarian Neoplasms; Safety

2003

Trials

3 trial(s) available for lonidamine and Cancer of Ovary

ArticleYear
Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer.
    European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance; Epirubicin; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Salvage Therapy

1994
Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Drug Synergism; Female; Humans; Indazoles; Middle Aged; Ovarian Neoplasms

1997
Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study.
    European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome

2001

Other Studies

6 other study(ies) available for lonidamine and Cancer of Ovary

ArticleYear
Doxorubicin combined with betulinic acid or lonidamine in RGD ligand-targeted pH-sensitive micellar system for ovarian cancer treatment.
    International journal of pharmaceutics, 2019, Nov-25, Volume: 571

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arginine; Aspartic Acid; Betulinic Acid; Cell Line, Tumor; Doxorubicin; Drug Carriers; Drug Compounding; Drug Liberation; Female; Glycine; Humans; Hydrogen-Ion Concentration; Indazoles; Leukocyte Count; Ligands; Mice; Micelles; Oligopeptides; Ovarian Neoplasms; Pentacyclic Triterpenes; Tissue Distribution; Triterpenes; Xenograft Model Antitumor Assays

2019
Lonidamine induces intracellular tumor acidification and ATP depletion in breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin.
    NMR in biomedicine, 2015, Volume: 28, Issue:3

    Topics: Acids; Adenosine Triphosphate; Animals; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; Drug Synergism; Energy Metabolism; Female; Humans; Hydrogen-Ion Concentration; Indazoles; Intracellular Space; Magnetic Resonance Spectroscopy; Male; Mice, Nude; Monocarboxylic Acid Transporters; Ovarian Neoplasms; Prostatic Neoplasms; Symporters; Xenograft Model Antitumor Assays

2015
Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells.
    Molecular pharmaceutics, 2011, Feb-07, Volume: 8, Issue:1

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Resistance, Multiple; ErbB Receptors; Female; Humans; Indazoles; Nanoparticles; Ovarian Neoplasms; Paclitaxel; Polymers

2011
An on-line semi-automated solid-phase extraction procedure for high-performance liquid chromatographic determination of lonidamine in serum.
    Journal of pharmaceutical and biomedical analysis, 1995, Volume: 13, Issue:11

    Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Female; Humans; Indazoles; Ovarian Neoplasms

1995
Lonidamine as a modulator of taxol activity in human ovarian cancer cells: effects on cell cycle and induction of apoptosis.
    International journal of cancer, 1998, Oct-29, Volume: 78, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Caspases; Cell Cycle; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Synergism; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Mitotic Index; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerases; Protamine Kinase; Tubulin; Tumor Cells, Cultured; Tumor Suppressor Protein p53

1998
Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells.
    International journal of cancer, 1992, Nov-11, Volume: 52, Issue:5

    Topics: Cell Cycle; Cell Survival; Cisplatin; Cross-Linking Reagents; DNA Damage; Dose-Response Relationship, Drug; Drug Resistance; Drug Synergism; Female; Humans; In Vitro Techniques; Indazoles; Ovarian Neoplasms; Tumor Cells, Cultured

1992